Carvedilol analogue inhibits triggered activities evoked by both early and delayed afterdepolarizations

Heart Rhythm

Volumn 10, Issue 1, 2013, Pages 101-107

  Maruyama, Mitsunori ^a,d   Xiao, Jianmin ^b   Zhou, Qiang ^b   Vembaiyan, Kannan ^b   Chua, Su Kiat ^a   Rubart Von Der Lohe, Michael ^c   Lin, Shien Fong ^a   Back, Thomas G ^b   Wayne Chen, Sr ^b   Chen, Peng Sheng ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Afterdepolarization; Intracellular calcium; Long QT syndrome

Indexed keywords

CALCIUM; CARVEDILOL; ISOPRENALINE;

ARTICLE; ATRIOVENTRICULAR BLOCK; CALCIUM CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART DEPOLARIZATION; HEART VENTRICLE TACHYCARDIA; ISOLATED HEART; LONG QT SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84872040278     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.09.006     Document Type: Article

References (29)

1. H.A. Fozzard Afterdepolarizations and triggered activity Basic Res Cardiol 87 1992 105 113
2. M.J. Janse Electrophysiological changes in heart failure and their relationship to arrhythmogenesis Cardiovasc Res 61 2004 208 217
3. S.M. Pogwizd, and D.M. Bers Cellular basis of triggered arrhythmias in heart failure Trends Cardiovasc Med 14 2004 61 66
4. S.M. Pogwizd, J.P. McKenzie, and M.E. Cain Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy Circulation 98 1998 2404 2414
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. Lancet 1999;353:2001-2007.
6. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. CIBIS-II Investigators and Committees. Lancet 1999;353:9-13.
7. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial Investigators, N. Engl J. Med 2001;344:1659-1667.
8. P.A. Poole-Wilson, K. Swedberg, and J.G. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial Lancet 362 2003 7 13
9. M. Packer, M.R. Bristow, and J.N. Cohn S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
10. P.R. Kowey A review of carvedilol arrhythmia data in clinical trials J Cardiovasc Pharmacol Ther 10 2005 S59 S68
11. N. El-Sherif, and G. Turitto Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent? Pacing Clin Electrophysiol 28 2005 985 990
12. Q. Zhou, J. Xiao, and D. Jiang Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca(2+) release Nat Med 17 2011 1003 1009
13. P.G. Volders, M.A. Vos, and B. Szabo Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts Cardiovasc Res 46 2000 376 392
14. 2+ triggers early afterdepolarizations and torsade de pointes in rabbit hearts with type 2 long QT syndrome J Physiol 543 2002 615 631
15. M. Maruyama, S.F. Lin, and Y. Xie Genesis of phase 3 early afterdepolarizations and triggered activity in acquired long-QT syndrome Circ Arrhythm Electrophysiol 4 2011 103 111
16. M. Maruyama, B. Joung, and L. Tang Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of Purkinje fibers and triggered activity Circ Res 106 2010 399 408
17. C.S. Kuo, K. Munakata, C.P. Reddy, and B. Surawicz Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations Circulation 67 1983 1356 1367
18. 2+ sensitivity of the ryanodine receptor mutant RYR2 R4496C underlies catecholaminergic polymorphic ventricular tachycardia Circ Res 104 2009 201 209
19. 2+ spark mass J Mol Cell Cardiol 48 2010 293 301
20. 2+ release channels (RYR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia Circ Arrhythm Electrophysiol 4 2011 128 135
21. Y.S. Lee, M. Maruyama, and P.C. Chang Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles Heart Rhythm 9 2012 1125 1132
22. C.E. Clancy, and Y. Rudy Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia Nature 400 1999 566 569
23. C. Antzelevitch Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol 37 2004 15 24
24. M.A. Vos, J.M. van Opstal, J.D. Leunissen, and S.C. Verduyn Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias Pharmacol Ther 92 2001 109 122
25. E. Patterson, B. Szabo, B.J. Scherlag, and R. Lazzara Early and delayed afterdepolarizations associated with cesium chloride-induced arrhythmias in the dog J Cardiovasc Pharmacol 15 1990 323 331
26. S.G. Priori, and P.B. Corr Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines Am J Physiol 258 1990 H1796 H1805
27. J.N. Weiss, A. Garfinkel, H.S. Karagueuzian, P.S. Chen, and Z. Qu Early afterdepolarizations and cardiac arrhythmias Heart Rhythm 7 2010 1891 1899
28. H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380 383
29. A. Parikh, R. Mantravadi, and D. Kozhevnikov Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2 Heart Rhythm 9 2012 953 960